AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 291 min read$BMY

Bristol Myers Squibb 3Q 2026: Revenue $13.07B, EPS $1.05— 10-Q Summary

Bristol Myers Squibb reported 3Q 2026 revenue of $13.07B, up 6.9% YoY, with net income of $2.16B, down 1.5%, and EPS of $1.05, down 2.8%. Growth portfolio sales rose 12%, while Opdivo sales declined. U.S. Eliquis sales increased 39%, and the company announced new drug approvals and manufacturing plans.

Original reporting
tradingview.com
Published Oct 29, 2026, 3:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb 3Q 2026: Revenue $13.07B, EPS $1.05— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$BMYBearishMed
01

Why it matters

Earnings release provides fresh data on revenue growth and EPS decline, influencing short‑term price action.

02

Market read

Primary earnings disclosure for a major pharma player; relevant for traders in healthcare sector.

03

What to watch

Potential cost‑saving from upcoming $2B productivity initiative could boost future margins.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

The article summarizes Bristol Myers Squibb's Q3 2026 earnings filing.

Company-level read

Ticker impact

$BMYBearishHigh confidence
Context

Bristol Myers Squibb reported Q3 2026 revenue of $13.07B and diluted EPS of $1.05, a 6.9% revenue increase but a 2.8% EPS decline.

Expected impact

likely modest downside as the market prices in the EPS decline

Evidence & confidence

The EPS fell 2.8% year‑over‑year, which could trigger short‑term selling pressure even though revenue rose.

Market effects

Sector

Pharma sector may see mixed reaction as revenue growth offsets earnings miss.

Regional

U.S. biotech stocks could experience slight pullback.

Global

Limited to healthcare investors; no broad market effect.

Counterpoint

What could challenge this read

The revenue beat may support a longer‑term upside if cost controls improve.

Key entities

  • company
    Bristol Myers Squibb

    Large‑cap pharmaceutical company reporting Q3 2026 results.

Read at source← All news

StoryBristol‑Myers Squibb posts Q3 beat, lifts 2026 revenue outlook and trims full‑year EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min
OCT 29
$NVSLow

4 Long-Term Survival Results From ESMO 2026 Patients Should Know

Novartis reported 6-year data from the NATALEE trial showing Kisqali (ribociclib) reduced death risk by 19% in early breast cancer. Merck's Keytruda (pembrolizumab) showed 7-year survival benefits in kidney cancer. Bristol-Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated lasting survival in colorectal cancer. Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations showed 3-year survival gains in stomach/esophageal cancer. All treatments were FDA-approved previously.

curetoday.com3 min
OCT 29
$BMYMedAI 8/10

BMS Flounders As Opdivo Lags, Earnings Guidance Cut

Bristol Myers Squibb (BMY) reported Q3 adjusted earnings of $1.35 per share, beating estimates of $1.10, with revenue of $13.07B, also exceeding expectations. The company cut its full-year earnings guidance due to weaker-than-expected sales of its cancer drug, Opdivo. BMY shares declined on the news.

investors.com2 min
OCT 29
$BMYHighAI 9/10

Why is Bristol-Myers Squibb stock gaining today?

Bristol-Myers Squibb (BMY) stock rose 1.5% in pre-market trading after reporting Q3 2026 adjusted EPS of $1.35, beating estimates of $1.09–$1.10, and revenue of $13.07 billion, exceeding forecasts of $12.72 billion. The company raised its full-year 2026 revenue guidance to $49.75–$50.25 billion. Growth Portfolio revenue increased 12% year-over-year to $7.7 billion. The stock traded lower than its 52-week high ahead of earnings.

investing.com4 min